Volume 27, Number 9—September 2021
Research
Genomic Epidemiology of Azithromycin-Nonsusceptible Neisseria gonorrhoeae, Argentina, 2005–2019
Table 2
Antimicrobial susceptibility of 96 azithromycin-resistant Neisseria gonorrhoeae isolates, Argentina, January 2005–November 2019*
Antimicrobial drug | Azithromycin MICs, μg/mL (no. isolates) |
||||||
---|---|---|---|---|---|---|---|
2–16 (91) |
>256 (5) |
||||||
MIC50 | MIC90 | Range | Resistance, % | MIC | Resistance, % | ||
Ciprofloxacin | 0.004 | 16 | 0.001–32 | 28.6 | 0.002–4 | 20 | |
Tetracycline | 1 | 2 | 0.125–4 | 25.3 | 0.5–2 | 20 | |
Benzylpenicillin | 1 | 2 | 0.25–8 | 14.3 | 0.5–1 | 0 | |
Ceftriaxone | 0.004 | 0.03 | 0.002–0.06 | 0 | 0.004–0.016 | 0 | |
Cefixime | 0.016 | 0.03 | 0.004–0.125 | 0 | 0.008–0.03 | 0 | |
Spectinomycin | 32 | 32 | 16–32 | 0 | 32 | 0 | |
Gentamicin | 8 | 8 | 4–16 | 0 | 8–16 | 0 |
*MIC50, MIC for 50% of isolates; MIC90, MIC for 90% of isolates.
1Members of this group are listed at the end of the article.